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Abstract
Background: The human granulocyte colony-stimulating factor (G-CSF) is routinely
applied to support recovery of granulopoiesis during the course of cytotoxic
chemotherapies. However, optimal use of the drug is largely unknown. We showed in
the past that a biomathematical compartment model of human granulopoiesis can be
used to make clinically relevant predictions regarding new, yet untested chemotherapy
regimen. In the present paper, we aim to extend this model by a detailed
pharmacokinetic and -dynamic modelling of two commonly used G-CSF derivatives
Filgrastim and Pegfilgrastim.
Results: Model equations are based on our physiological understanding of the drugs
which are delayed absorption of G-CSF when applied to the subcutaneous tissue,
dose-dependent bioavailability, unspecific first order elimination, specific elimination in
dependence on granulocyte counts and reversible protein binding. Pharmacokinetic
differences between Filgrastim and Pegfilgrastim were modelled as different parameter
sets. Our former cell-kinetic model of granulopoiesis was essentially preserved, except
for a few additional assumptions and simplifications. We assumed a delayed action of
G-CSF on the bone marrow, a delayed action of chemotherapy and differences
between Filgrastim and Pegfilgrastim with respect to stimulation potency of the bone
marrow. Additionally, we incorporated a model of combined action of Pegfilgrastim
and Filgrastim or endogenous G-CSF which interact via concurrent receptor binding.
Unknown pharmacokinetic or cell-kinetic parameters were determined by fitting the
predictions of the model to available datasets of G-CSF applications, chemotherapy
applications or combinations of it. Data were either extracted from the literature or
were received from cooperating clinical study groups. Model predictions fitted well to
both, datasets used for parameter estimation and validation scenarios as well. A unique
set of parameters was identified which is valid for all scenarios considered. Differences
in pharmacokinetic parameter estimates between Filgrastim and Pegfilgrastim were
biologically plausible throughout.
Conclusion: We conclude that we established a comprehensive biomathematical
model to explain the dynamics of granulopoiesis under chemotherapy and
applications of two different G-CSF derivatives. We aim to apply the model to a large
variety of chemotherapy regimen in the future in order to optimize corresponding
G-CSF schedules or to individualize G-CSF treatment according to the granulotoxic risk
of a patient.
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The human granulocyte colony-stimulating factor (G-CSF) is routinely applied in various
cancer chemotherapy regimen in order to ameliorate or prevent neutropenia caused
by the unspecific toxicity of the drugs used [1-4]. G-CSF proved to be highly potent
in stimulating granulopoiesis via several modes of action such as mitotic activation of
granulopoietic progenitors and precursors, accelerated maturation of bone marrow cell
stages and increased release of mature bone marrow cells [5-10].
In case of conventional (non-myeloablative) chemotherapies, the haematopoietic
system usually recovers without further medication. But, G-CSF can significantly speed
up this process allowing dose- and time-intensifications of multi-cycle chemotherapies
[11,12]. While platelets and red blood cells can show cumulative toxicity during the
course of intensified regimen, appropriate G-CSF prophylaxis often results in a complete
recovery of circulating granulocytes within one therapy cycle, i.e. within two or three
weeks [4,13].
Several pharmaceutical derivatives of G-CSF are available now. The first gener-
ation of G-CSF pharmaceuticals were recombinant derivatives such as Filgrastim
(non-glycosylated) or Lenograstim (glycosylated). Both derivatives are virtually identical
to endogenously produced G-CSF [14-16] but Filgrastim is more frequently used in
clinical trials. Filgrastim is eliminated by both, renal elimination and specific degrada-
tion mediated by G-CSF receptors or neutrophil elastase [17-22]. This results in a short
half-life in vivo requiring multiple injections during one cycle of chemotherapy. As next
generation G-CSF derivative, Pegfilgrastim (pegylated Filgrastim) was developed in order
to improve the pharmaceutical properties of Filgrastim. Indeed, Pegfilgrastim shows a
remarkably prolonged half-life in vivo mainly due to reduced renal clearance [23-25].
Therefore, only one injection (with fixed dose) is required during one chemotherapy
cycle. On the other hand, pegylation of proteins also might reduce the receptor binding
affinity, and withit, the efficacy of the drug [26-29]. But for Pegfilgrastim, this effect
appears to be less important than the gain in half-life, since it is generally believed
that a single injection of Pegfilgrastim is at least as effective as multiple injections of
Filgrastim in treating neutropenia [2,30-33]. There are some ongoing efforts to further
improve the pharmacokinetic properties of G-CSF derivatives by additional pegylations
(e.g. Maxy-G34, [29]). Although the application of pegylated G-CSF is much more con-
venient for both patients and clinicians, we believe that Filgrastim will not completely be
replaced since it can be applied more individually e.g. in dependence on the neutropenic
risk of a patient or in cases when granulopoietic recovery is insufficient while pegy-
lated G-CSF was applied [34]. Additionally, for the purpose of stem cell mobilization,
Filgrastim is not inferior compared to Pegfilgrastim but has less severe side-effects [35].
In view of the highly differing pharmacokinetic properties of the available G-CSF
derivatives, we constructed pharmacokinetic models of the G-CSF derivatives Filgrastim,
Pegfilgrastim and the novel Maxy-G34 in mice and rats [29,36]. Our aim was to iden-
tify basic pharmacokinetic model mechanisms especially with respect to the degradation
of G-CSF in vivo and to compare the resulting pharmacokinetic parameters between the
G-CSF derivatives. We now aim to translate these model insights to humans.
Effectiveness of G-CSF treatment depends on many variable therapy parameters such
as applied chemotherapy, individual factors, G-CSF derivative used, and especially, its
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dosing and timing schedule [4,34,37,38]. Chemotherapy induced neutropenia and G-CSF
induced granulocytosis via differentmodes of action in combination with a strong specific
elimination of G-CSF mediated by circulating granulocytes results in complex dynamics
of both G-CSF serum concentration and circulating granulocytes as well. In consequence,
the optimization of G-CSF treatment is a non-trivial task and cannot be performed solely
on the basis of clinical trials. We showed in the past that biomathematical cell-kinetic
models of granulopoiesis under chemotherapy and G-CSF support are useful to opti-
mize chemotherapy regimen regarding granulotoxicity [39-41]. Our formermodel already
included a preliminary model of Filgrastim application. In the present paper, we update
our model with respect to improved pharmacokinetic and dynamic modelling of Filgras-
tim and Pegfilgrastim based on our models in mice. Additionally, our cell-kinetic model
has been improved by a more elaborated model of chemotherapy action. The resulting
model is now able to explain the time courses of granulocytes and G-CSF serum con-
centrations for virtually all datasets published in the literature. We also discuss how the
model can be used to optimize G-CSF scheduling of chemotherapies.
Structure of the humanmodel of granulopoiesis under chemotherapy with G-CSF support
Our cell kinetic model of granulopoiesis is an ordinary differential equations system
modelling the time-dependent content of and the fluxes between the following cell com-
partments: S (pluripotent stem cells), CG (colony forming units of granulocytes and
macrophages), PGB (proliferating granulopoietic blasts), MGB (maturing granulopoietic
blasts - subdivided into metamyelocytes (G4), banded granulocytes (G5) and segmented
granulocytes (G6)) andGRA (circulating granulocytes). At this, the efflux of one compart-
ment equals the influx of the subsequent compartment. The system is highly regulated
via growth factor mediated feedback loops. The most important one is G-CSF which reg-
ulates the compartments CG, PGB and MGB, but not S [5-10,42,43]. Modes of action
comprise improvement of proliferation, acceleration of maturation and improvement of
the release of mature blood cells from bone marrow to blood. The latter one is also
denoted as postmitotic amplification in the following. Production and consumption of
G-CSF are regulated by mature cells. We also modelled a subcutaneous compartment in
which G-CSF is usually injected. Chemotherapy induces an instantaneous depletion of
bone marrow cell stages which is specific for each cell stage and dependent on the applied
drugs and drug doses. The cell-kinetic model is essentially the same as presented and dis-
cussed in [40], except for a few changes which we will discuss later. Basic model structure
is shown in Figure 1. A complete set of model equations and parameters is presented in
the Additional file 1.
For unperturbed granulopoiesis, the model is autonomous and has a single fixed-
point (steady-state). This fixed-point appears to be stable for the parameter set which
we propose later, i.e. transient perturbations result in damped oscillations until the
fixed-point is re-established. Permanent perturbations such as constant G-CSF stimu-
lation or chemotherapy damage result in new fixed-points of increased or depressed
granulopoiesis, respectively.
However, stable oscillations of the system can occur for alternative parameter sets
especially if parameters of stem cell regulation are changed.
In general, we assume that the system is in steady-state at the beginning of any
treatment. That is, initial values equals normal values.


































Figure 1 (Basic structure of the cell-kinetic model of granulopoiesis).Major model compartments
describing granulopoietic cell stages are S (pluripotent stem cells), CG (colony forming units of granulocytes
and macrophages), PGB (proliferating granulopoietic blasts),MGB (maturing granulopoietic blasts -
subdivided into metamyelocytes (G4),banded granulocytes (G5) and segmented granulocytes (G6)) and GRA
(circulating granulocytes). The system is regulated by feedback loops. A major loop is mediated by G-CSF
which is produced endogenously but can also be applied subcutaneously. Chemotherapy (CX) induces
acute cell loss. The model is essentially the same as in [40].
Basic model mechanisms
In this section, we briefly describe two important regulation mechanisms of our gran-
ulopoiesis model which are needed in the following. A more detailed discussion of all
regulation mechanisms of the model is given in [40].
Z-function
Most of our cell kinetic parameters such as amplification or transition times are regulated
between a minimum and a maximum value by a so called Z-function, which is a function
of another quantity such as circulating G-CSF. We use the following class of Z-functions:










for Ymin < Ynor < Ymax or Ymin > Ynor > Ymax
Ynor for Ymin = Ynor = Ymax
, (1)
where X is the regulator of the quantity Y and Ymin, Ynor , Ymax, bY are the parameters
of the Z-function for the regulation of Y. The parameter bY defines the steepness of the
function and is called sensitivity parameter in the following.
Modelling of delays
The maturation of cells and the transition between maturing compartments is neither a
random first order transition without dependence of cell age (which is equivalent to an
exponential distribution of transit times) nor a transition with fixed time delay. In [40]
we showed that a cascade of first order transitions results in a Gamma distribution of
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the transition times. More precisely, if we divide a compartment with transit time T in
N subcompartments connected by first order transitions with time T/N , the resulting
distribution is a Gamma distribution with expectation T and variance T2/N . Hence, the
number of subcompartments corresponds to a variance estimate regarding the transition
time.
The method of dividing compartments into subcompartments in order to introduce




Our pharmacokinetic model of G-CSF is essentially based on models developed for mice
and rats [29,36]. The underlying model assumptions are as follows:
1. The pharmacokinetic model contains three compartments in which G-CSF is
present: The subcutaneous compartment CscG−CSF in which G-CSF is usually
injected, the central compartment CcentG−CSF in which G-CSF is haematologically
active and a peripheral compartment CperG−CSF representing reversible bindings of
G-CSF (e.g. protein binding [44]).
2. Subcutaneously injected G-CSF results in a delayed influx of G-CSF into the central
compartment caused e.g. by lymphatic absorption [45]. The delay is modelled by
the division of the subcutaneous compartment into two subcompartments.
3. Transitions between central and peripheral compartment are reversible and are
modelled by a first order kinetic in both directions [46].
4. Endogenous G-CSF is produced by endothelial cells [47]. The production is
regulated by the demand of mature granulocytes. We implemented a
phenomenological rather than mechanistic modelling of this principle. At this, the
production of endogenous G-CSF is modelled as a function of the content of the
final bone marrow compartment and circulating granulocytes. This is in complete
analogy to former versions of our model [40].
5. Since the bioavailability of G-CSF derivatives is dose-dependent [29], we assume
that a part of the applied G-CSF is removed from the subcutaneous compartment
without entering the central compartment. This is modelled by a Michaelis-Menten
kinetic within the first subcompartment of the subcutaneous tissue.
6. G-CSF is irreversibly removed from the central compartment by two independent
processes: An unspecific renal elimination which is modelled by a first order
kinetic [24,46] and a specific degradation mediated by the number of circulating
granulocytes. The latter one is modelled by a Michaelis-Menten kinetic which is
assumed to be proportional to the number of circulating granulocytes [36,48-51].
Two key mechanisms are discussed for the specific degradation which are cleavage
by neutrophil elastase [20,21,52,53] and G-CSF receptor binding and internalization
[19,22,54-56]. Since neutrophil elastase is mainly produced by granulocytes [20],
proportionality of degradation with granulocyte count can be assumed for the first
mechanism. For the second mechanism, the proportionality assumption is less
clear since the majority of G-CSF receptors are within the bone marrow which
dynamics are somewhat different from the dynamics of mature granulocytes.
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7. Differences in G-CSF derivatives are model by different model parameters rather
than differences in model structure. In view of the high similarity of Filgrastim and
endogenous G-CSF [14-16], we assume that the pharmacokinetic and -dynamic
parameters of Filgrastim and endogenous G-CSF are the same. In contrast, we
assume differences between Filgrastim and Pegfilgrastim for some of the
parameters. More precisely, pharmacokinetic differences were assumed with
respect to absorption, distribution and degradation of the G-CSF pharmaceuticals
in order to model observed differences in G-CSF serum dynamics after
subcutaneous applications [23-25]. Pharmacodynamik differences are modelled by
different parameterizations of the G-CSF mediated regulatory mechanisms
(Z-functions). The latter is motivated by experimental results suggesting a reduced
receptor binding affinity of pegylated G-CSF [26-29].
Based on these assumptions, we formulate the pharmacokinetic model equations in the
next section. A schematic structure of the model can be found in Figure 2.
Pharmacokinetic model equations
Endogenous production
According to [40], the relative G-CSF production PendoG−CSF is a Z-function of the relative







where ωG6 and ωGRA are weighting parameters. It holds that Pendo_norG−CSF = 1 whereas all
other parameters of the Z-functions are free parameters.
Exogenous G-CSF application
Exogenous G-CSF applications are modelled by an injection function. Let
Hv(t) =
{
0 : t ≤ 0
1 : t > 0





Hv (t − ti) − Hv
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Figure 2 (Model structure of the pharmacokinetic model of G-CSF). The major compartments, cytokine
fluxes and regulations are presented (MM = Michaelis Menten kinetic). The subcutaneous compartment is
divided into two subcompartments with first order transition.
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where ti ≥ 0 (i = 1, . . . , L) are the time points of G-CSF injections and dG−CSF (ti) are the
corresponding doses (in μg). The parameter tinf is the duration of the injection which we
assumed to be constant (tinf = 5s).
The injection function is specific for each G-CSF derivative and site of injection
(subcutaneous, intravenous). That is, for concurrent Filgrastim and Pegfilgrastim appli-
cations injections at concurrent sites one needs a maximum of four injection functions
Pexo_sc_filG−CSF , P
exo_iv_fil
G−CSF for subcutaneous and intravenous Filgrastim injections and P
exo_sc_peg
G−CSF
and Pexo_iv_pegG−CSF for subcutaneous and intravenous Pegfilgrastim injections respectively.
Subcutaneous compartment
The subcutaneous compartment is divided into two subcompartments sc_1 and sc_2
where the efflux of the first compartment is the influx to the second compartment. G-CSF
is applied to the first subcompartment (second term of (4)). In the first subcompartment
there is a dose-dependent loss of G-CSF modelled by a Michaelis-Menten kinetic (third


















with the initial values Csc_1G−CSF(0) = Csc_2G−CSF(0) = 0. For Pegfilgrastim injections the
first term of the right-hand side of (4) is substituted by Pexo_peg_scG−CSF . Likewise, the Filgrastim
parameters kFsc, vFmax and kFm are substituted by corresponding Pegfilgrastim parameters.
Central compartment




G−CSF = PrefG−CSFPendoG−CSF + Pexo_fil_ivG−CSF + kFscCsc_2G−CSF (6)






The balance equation (6) contains terms in the following order: The endogenous produc-
tion, a potential intravenous injection, the influx from the subcutaneous compartment,
the unspecific elimination, the efflux to the peripheral compartment, the influx from the
peripheral compartment and the specific elimination (Michaelis-Menten kinetic) which is
proportional to the relative granulocyte concentrationCrelGRA. The corresponding equation
for Pegfilgrastim is the same except for the endogenous production, which is zero, the
intravenous injection function which is substituted by Pexo_peg_ivG−CSF , the parameters and the
initial value which is again zero.
The relative endogenous production function of G-CSF is multiplied by a constant
PrefG−CSF in order to adjust the normal value of CcentG−CSF to a reference amount of G-CSF
which is the product of the distribution volume VFD and the reference G-CSF serum
concentration Ccent_refG−CSF which will be determined later on the basis of measurements
available from the literature. Assume that CcentG−CSF(0) = Ccent_norG−CSF = VFDCcent_refG−CSF , the
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parameter PrefG−CSF can be calculated exploiting the steady-state conditions of equation













G−CSF = kcpCcentG−CSF − kpcCperG−CSF (8)




where the parameters kcp, kpc and VD are specific for Filgrastim and Pegfilgrastim
respectively.
New pharmacodynamic model assumptions
The pharmacodynamic model describes the dynamics of the bone marrow cell stages, cir-
culating granulocytes, G-CSF, corresponding regulations and the action of chemotherapy
as well. In Table 1 we present the major model compartments and its regulatory features.
A complete set of equations can be found in the Additional file 1.
We used the same pharmacodynamic model of G-CSF as presented in [40] except for a
few simplifications and additional assumptions which we will discuss now:
1. The cytokine GM-CSF (granulocyte macrophage colony-stimulating factor) was no
longer considered in order to simplify the model. Since the endogenous productions
of GM-CSF and G-CSF in our former model were both related to the demand of
bone marrow cell stages, the time courses of endogenous G-CSF and GM-CSF after
external perturbations are similar, making the cytokines undistinguishable from the
modelling point of view (compare [40]). Therefore, only G-CSF was considered in the
present model. It replaces GM-CSF regarding the regulation of the CG
Table 1Major compartments of the pharmacokineticmodel and corresponding regulations
Compartment Regulations Regulator
S proliferative fraction bone marrow content
self-renewal probability bone marrow content





MGB post-mitotic amplification G-CSF
transition time G-CSF
GRA turn-over -
G-CSF endogenous production late bone marrow cell stages
specific degradation GRA
external applications -
Most of these compartments are mediated by G-CSF. A complete set of model equations can be found in the Additional file 1.
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compartment. This simplification is also biologically plausible since G-CSF receptors
are also expressed at myeloid progenitors [42].
2. The transition times TCG and TPGB were constant in our former version of the model
but are now dependent on G-CSF via a Z-function. This model assumption was
made in order to account for the increased number of mitoses in these
compartments. But, due to the lack of data, it must be considered as speculative.
3. Since Pegfilgrastim and Filgrastim are supposed to have different G-CSF receptor
binding affinities [26-29], we assume different regulatory Z-functions for both
derivatives. But we assumed the same pharmacodynamic parameters for Filgrastim
and endogenously produced G-CSF.
4. While in our former model version the G-CSF concentration instantaneously
affected the value of the Z-functions, we now introduce a time delay regarding
G-CSF action. This was motivated by transduction network analyses which revealed
a delayed response of the transcriptome to G-CSF stimulations [57]. The delay is
modelled by a cascade of four subcompartments (see section “Basic model
mechanisms”). The efflux of the last subcompartment is the delayed G-CSF












i = 2, . . . , 4 (11)
with Ccent_rel_delG−CSF = DG−CSF · C4G−CSF . The delay parameter DG−CSF is specific for






for all quantities Y regulated by G-CSF. At this, the normal value of the Z-function
Ynor refers to CnorG−CSF for endogenous G-CSF or Filgrastim and to an absolute
amount of 1μg for Pegfilgrastim.
5. In case of Pegfilgrastim injections, Pegfilgrastim and endogenous G-CSF compete
with respect to receptor binding. To model this process, the Z-functions of
Pegfilgrastim and Filgrastim were added using a weighting factor ωP which is again a








with ωminP = 0 and ωmaxP = 1









where Y is an arbitrary regulated quantity such as a transition time or an
amplification. For all these quantities we assumed the same Z-function of the
weighting parameter ωP .
6. In the previous version of our model, chemotherapy was modelled by an
instantaneous depletion of bone marrow cells lasting exactly one day. Since
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independence of cytotoxic action of the single chemotherapy components was
assumed, the effect of chemotherapy could be modelled by a step function with a step
width of one day. Although the metabolism of cytotoxic drugs is usually fast, the
nadir of bone marrow cell stages is typically reached a few days after the application
[58]. To account for this observation, we delayed the toxic effect of chemotherapy
applications by a cascade of four subcompartments in complete analogy to (10), (11)
resulting in a delayed toxicity function GRA. The delay parameter is specific for the
cytotoxic drugs used. Hence, two parameters are required to define the toxic effect of
a chemotherapeutic drug to a single cell line: a delay parameter and a scaling factor of
the toxicity function.While the delay is only specific for the applied chemotherapeutic
drug but constant for all cell stages, the scaling factor is specific for both.
7. Since our model is a model of granulopoiesis, we can only make predictions for
absolute neutrophil counts. However, in clinical practice often only leukocytes are
available. In our former model version, we assumed proportionality of leukocytes and
absolute neutrophil count which is only roughly correct [38,40]. To be more precise,
we now calculate the leukocyte count as the sum of lymphocytes and granulocytes.
To avoid a full model of lymphopoiesis, we modelled the reduced lymphocyte count
under chemotherapy by an exponential function of the corresponding toxicity
function.
CWBC(t) ≈ cLY exp
(−LY (t))+ cGRACGRA(t)CnorGRA (15)
where cLY = 3000 cells per μl and cGRA = 4000 cells per μl are the normal
concentrations of lymphocytes and granulocytes respectively. LY is the toxicity
function for lymphocytes which is analogously defined as the toxicity functions of
granulopoiesis (see 6.)
Construction of toxicity functions
Since the precise structure of the toxicity function depends on the schedule of the
chemotherapy, we demonstrate the construction of the toxicity functions using six cycles
of CHOP therapy with a cycle duration of 14 days (6xCHOP-14) as example. During
CHOP-14 therapy, the cytotoxic drugs cyclophosphamide, doxorubicine and vincristine
are applied concomitantly at the first day of each cycle. Since contributions of these drugs
to granulotoxicity cannot be separated, we assume a unique toxicity function for this drug






Hv (t − 14d · (i − 1)) − Hv
(
t − 14d · (i − 1) − tinf6×CHOP−14
)
tinf6×CHOP−14
which is in analogy to (3). Here, no dose parameter is required since intensity of damage
is defined by the toxicity parameters later. We set tinf6×CHOP−14 = 1d. The delayed action
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where i = 2, . . . , 4, X ∈ {LY ,GRA}, i.e. the delay parameter D is specific for each
chemotherapy and different for the toxicity functions of granulocytes and lymphocytes.
Now, the toxicity functions are defined as:
LY6×CHOP−14 = kLY · DLY6×CHOP−14 · LY_46×CHOP−14

GRA_Y
6×CHOP−14 = kY · DGRA6×CHOP−14 · GRA_46×CHOP−14
where k are the toxicity parameters and Y  {S,CG,PGB,MGB}, i.e. the toxicity function
is specific for the different cell stages of granulopoiesis. If drugs are applied at different
schedules, corresponding toxicity functions are added. The sketched principle can easily
be generalized to derive toxicity functions of arbitrary chemotherapy schedules.
Model calibration, parameter estimation and validation
Estimation of parameters
A main goal of our study is to construct pharmacokinetic models of Filgrastim and Peg-
filgrastim. Based on the pharmacokinetic model equations presented above, a set of
unknown pharmacokinetic parameters needs to be determined.
Since detailed bone marrow data of human granulopoiesis are not available, most of
the bone marrow parameters are only known up to a certain range or are completely
unknown. Furthermore, model parameters regarding sensitivity of regulatory mecha-
nisms (sensitivity parameters) have no direct biological measurable equivalent. Finally,
we want to apply the model to chemotherapy settings requiring a quantification of cor-
responding toxicity and delay parameters. Many of the parameters of the present model
version were adopted from an earlier version of the model especially if they are not very
sensitive regarding model behaviour (compare [40]). But the inclusion of new regula-
tory mechanisms (see section “New pharmacodynamic model assumptions”) made some
adaptations of model parameters necessary.
To address these challenges, we established the following stepwise fitting procedure
keeping parameters identified at the previous step constant.
1. Pharmacokinetic model parameters were determined on the basis of available
cytokine dynamics after G-CSF application. In order to model the specific
elimination mechanism, we imprinted the corresponding data of granulocyte
dynamics at this stage of modelling. We obtained a unique parameter set which is
valid for all dosing and timing schedules of all scenarios considered.
2. Pharmacodynamic parameters were determined by fitting the predictions of the
model to available granulocyte and leukocyte dynamics of different scenarios
(G-CSF application and simple chemotherapies for which the number of
chemotherapy parameters to be fitted is relatively low). The resulting parameter set
is valid for all scenarios with and without chemotherapy applications. Since the
stem cell compartment is the basis of all of our models of haematopoietic lineages,
we decided to keep corresponding parameters constant and as presented in [40,59].
3. Afterwards, toxicity parameters of more complex chemotherapies can be
estimated. More details of chemotherapy modelling, parameter estimation and
exploration of patients with different risk of haematotoxicity can be found in a
separate publication of our group (Wetzler et al., to appear).
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A complete parameter list for our model is provided in the Additional file 1. Not all data
sets were used to fit parameters. A few data sets were kept in reserve in order to validate
the model.
Available data sets
Data sets were collected from the literature by an extensive search. For our modelling
purposes, close-meshed time series of G-CSF and absolute neutrophil counts (ANC) or
leukocytes are especially valuable. Corresponding data were extracted from the publi-
cations as precise as possible using automated tools. Data sets for which no means or
medians of the patients could be retrieved were neglected. Data sets comprise single or
multiple applications of G-CSF in healthy volunteers and conventional chemotherapies of
different diseases with or without G-CSF prophylaxis.
Additionally, we can rely on own clinical trials data for which one of us (Markus
Loeffler) is the responsible biostatistician or for which we have cooperation agreements.
Leukocyte raw data under chemotherapy are available from published studies of the
German High Grade Non-Hodgkin-Lymphoma Study Group. These studies were con-
ducted in accordance with the Declaration of Helsinki. Corresponding protocols were
approved by the ethics review committee of each participating center. Written informed
consent was obtained from the patient for publication of this report and any accompany-
ing images. An overview of data used for model fitting and validation is given in Table 2.
Fitting procedure
As mentioned above, unknown parameters of the model were determined by fitting the
predictions of the model to available clinical data minimizing the L1 distance between
logarithmized model and logarithmized median of data. More precisely, we have∫ t1
t0
∣∣ log(fmodel(t, k)) − log fdata(t)∣∣dt → mink , (16)
Table 2 Data sets utilized for the establishment and validation of the granulopoiesis model
Type of data Disease G-CSF schedules Chemotherapy References
Phase I studies none single application 3, 5, 10 μg/kg none [31]
with Filgrastim none single application 5, 10 μg/kg none [60]
none 10 applications 75, 150, 300, 600 μg none [61]
none 14 applications 30, 300 μg none [62]
none single application 4, 8 μg/kg none [63]
Phase I studies
with Pegfilgrastim none 30, 60, 100, 300 μg/kg none [50]
Phase II studies
with Pegfilgrastim LuCa 30, 100, 300 μg/kg none [64]
NHL 6000 μg, day 2 CHOP [65]
Phase III studies NHL no G-CSF CHOP-21* [12]
with CX and NHL 480 μg, day 4–13 CHOP-14* [12]
w/wo Filgrastim NHL 480 μg, day 6–12 CHOP-14* [66]
Phase III studies
with CX + Peg NHL 6000 μg, day 2, 4 CHOP-14* [67]
Studies with access to raw data are indicated with an asterisk. CX = chemotherapy, LuCa = lung cancer, NHL = high-grade
non-Hodgkin’s lymphoma.
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where fmodel(t, k) is the solution of the model equation system for the granulocyte com-
partment at the time t based on the parameter set k = k1, . . . kn. For each scenario, t0
and t1 describe the first and the last time point for which data are available. To obtain the
curve log fdata(t), the logarithms of the patients medians were linearly interpolated. Log-
arithms of data were used to provide an optimal fit of the nadir phase of cell counts. In
the following, the left hand side of equation (16) is referred to as the fitness function.
As in our previous papers, evolutionary strategies were used for the numerical solution
of the optimisation problem. This method is especially suitable for our problem since it
requires a minimum of computationally expensive calculations of the fitness function, it
can deal with a large number of free parameters with only a linear growth in effort and it
is the only chance to obtain a global optimum as good as possible.
Evolutionary strategies are non-deterministic optimization methods which are based
on the principles of evolution (mutation by chance, reproduction, realization of phe-
notypes and survival of the fittest). For mathematical optimisation, parameter settings
were taken instead of livings, that is parental parameter settings are changed by chance
(mutation), combined to form new parameter settings (reproduction) and were used to
solve the model equation system (realization). The parameter settings for which one
obtains a good agreement between the model prediction and the data were taken to cre-
ate the next generation of parameter settings (survival of the fittest). The fitness function
is a measure for this agreement. We used a (1+3) evolutionary strategy with self-adapting
mutation step size most of the time. That is, one possibly immortal parent creates three
children in each step. See also [68,69] for further details of evolutionary strategies.
Fitting of chemotherapy schedules requires additional parameters with respect to the
chemotherapy toxicity. The delay parameter of the toxicity is specific for each drug but is
the same for all bone marrow cell stages. Four toxicity parameters are required to model
the cell stage specific toxicities. Another parameter represents increased toxicity for the
first chemotherapy application (first cycle effect). Finally, two parameters represent the
toxicity to the lymphopoetic system (eq. (15)). In general, modelling a chemotherapy
required several sets of these parameters in order to model all drugs or drug combina-
tion with different schedules. However, for the purpose of model calibration, we only
considered simple chemotherapy schedules in order to reduce the number of additional
unknown parameters to be fitted. The CHOP regimens are based on the application of
three cytotoxic drugs (cyclophosphamide, doxorubicine and vincristine) at the same time.
Hence, only one set of chemotherapy parameters was assumed to model the effects of this
drug combination. Additionally, for these regimens different G-CSF schedules are avail-
able, which is especially useful for the calibration of our pharmacokinetic and -dynamic
models of Filgrastim and Pegfilgrastim.
Not all of our data sets were utilized for parameter fitting. A subset of data sets was kept
in reserve in order to validate the model. Data sets used for model validation comprise
the data of [63,65].
Sensitivity analysis
Since our model contains several parameters which are speculative or unknown only up
to a certain range, we peformed an extensive sensitivity analysis of all parameters. For
this purpose, parameters were increased or decreased by 2.5% and the corresponding
change of the fitness function was determined. At this, only affectedmodel scenarios were
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considered. The changes of the fitness function were plotted as bar diagrams for each
parameter in order to facilitate comparisons. Figures are shown in the Additional file 1.
Simulation and numerical methods
Our model has been programmed with MATLAB 7.5.0.342 (R2007b) and SIMULINK
toolbox (The MathWorks Inc., Natick, MA, USA). Simulations of the model were per-
formed by numerical integration of the equation system using the variable step solver
from Adams and Bashford implemented in the SIMULINK toolbox.
Results
Pharmacokinetic model of Filgrastim and Pegfilgrastim
Given the model equations of section “Pharmacokinetic model equations”, we determined
the pharmacokinetic parameters for Filgrastim and Pegfilgrastim separately by fitting the
model to time series of G-CSF serum concentrations after single or multiple application
of one of the two G-CSF derivatives. Parameter estimates are shown in Table 3.
Combined with our pharmacodynamicmodel (see section “The new pharmacodynamic
model”), these parameter estimates resulted in a good fit of all model scenarios. Examples
are presented in Figure 4. A complete list of all scenarios is presented in the Additional
file 1.
The new pharmacodynamic model
Unknown pharmacodynamic parameters were determined by fitting the predictions of
our model to available time courses of ANC or leukocytes after single or multiple injec-
tions of G-CSF or chemotherapy. All scenarios presented in section “Available data sets”
were used for this simultaneous fitting process except for those reserved for model vali-
dation (compare section “Fitting procedure”). Fitted parameters resulted in a good fit of
all model scenarios except for time points shortly after G-CSF injections. Examples are
shown in Figure 4. All other scenarios of G-CSF application can be found in the Additional
file 1. Chemotherapy scenarios are presented in the next section.
Table 3 Pharmacokinetic parameters of Filgrastim and Pegfilgrastim
Parameter Meaning Filgrastim Pegfilgrastim
ksc subcutaneous absorption [ h−1] 0.161 0.107
km Michaelis-Menten constant of 34.7 5.5
subcutaneous elimination [μg]
vmax Maximum of subcutaneous 67.3 16.5
elimination [ h−1]
ku unspecific elimination [ h−1] 0.441 0.087
kGRAm Michaelis-Menten constant of 22.4 30.8
specific elimination [μg]
vGRAmax Maximum of specific elimination [ h
−1] 4.77 5.16
kcp transition central to peripheral [ h−1] 0.000 0.075
kpc transition peripheral to central [ h−1] - 0.548
VD distribution volume [ l] 1.156 4.091





Compared to Pegfilgrastim, we estimated that Filgrastim is more easily absorbed from the subcutaneous compartment, has a
lower bioavailability (see Figure 3) and a higher specific and unspecific elimination. Reversible binding is neglectable for
Filgrastim but not for Pegfilgrastim. The distribution volume is higher for Pegfilgrastim than for Filgrastim.
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Figure 3 (Estimated bioavailability of subcutaneously injected Filgrastim or Pegfilgrastim based on
systematic model simulations): Bioavailability was estimated by calculating G-CSF amounts
absorbed by the central compartment relative and the total amount of subcutaneously injected
G-CSF (x-axis). Due to the modelled loss in the subcutaneous tissue, the bioavailability is dose-dependent.
Circles indicate estimates for pharmaceutically available doses of 300μg and 480μg of Filgrastim or 6000 μg
of Pegfilgrastim respectively [12,67].
The most sensitive pharmacodynamic parameters influencing the behaviour of the
model are parameters regarding the CG compartment (regulation of the proliferative frac-
tion, transition time and amplification), the amplification in the PGB compartment and
the postmitotic amplification. Sensitivity parameters of the regulation functions are gen-
erally less sensitive except for the sensitivity parameter of the regulation of the postmitotic
amplification. A complete list of the results of the sensitivity analysis can be found in the
Additional file 1.
Pharmacodynamic differences between Filgrastim and Pegfilgrastim can be traced back
to differences of the regulation functions. In general, compared to Pegfilgrastim, the regu-
lation functions of Filgrastim express a higher sensitivity regarding changes of the G-CSF
concentration, that is, greater slopes and higher values under maximum stimulation (see
Figure 5 for an example).
In contrast to our former model of granulopoiesis, we assumed a delayed effect of
G-CSF (assumption 4 in section “New pharmacodynamic model assumptions”). Conse-
quences of this assumption are studied in Figure 6 on the basis of model simulations of
single Filgrastim injections.
The estimated delay is moderate in size resulting in a small shift of the time course
of cell stages. This shift is negligible for MGB but more pronounced for the granulo-
cyte compartment which can be explained by the postmitotic amplification mechanism
(see [40]).
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l] Data 5 µg/kg
Model 5 µg/kg















B) Multiple injections of Filgrastim (Johnston et al., 2000)
Data 5 µg/kg
Model 5 µg/kg














































































Figure 4 (Comparison of model and data for G-CSF applications): Comparison of model and selected
datasets of single Filgrastim injections (scenario A), multiple Filgrastim injections (scenario B) and
single Pegfilgrastim injections of different doses (scenarios C and D). For each scenario, we present the
time courses of ANC and G-CSF, respectively. A complete list of scenarios can be found in the Additional file 1.
The new chemotherapy model
Chemotherapy was modelled by a transient depletion of bone marrow cell stages. In con-
trast to our former model of granulopoiesis, we assumed a delay of the bone marrow
depletion. The effect of this delay is studied in Figure 7.
The delay resulted in a later occurrence and a reduced depth of the nadir of leuko-
cytes. The delay was assumed to be different for different chemotherapeutic drugs or drug
combinations (see Wetzler et al. for further details).
Data of the CHOP regimen were utilized to fit both, the pharmacokinetic and -dynamic
model and the set of specific toxicity parameters as well. This set of toxicity parameters
was valid for all G-CSF schedules applied as supportive therapy for CHOP. Results of
these scenarios are shown in Figure 8.
Comparison of model and data revealed a good agreement. For almost all time points,
the model curve is within the interquartile range of the data. Chemotherapy and delay
parameters for the CHOP regimen can be found in the Additional file 1.

































Figure 5 (Regulation functions of Filgrastim and Pegfilgrastim): Comparison of Filgrastim and
Pegfilgrastim with respect to the regulation function of the amplification in PGB. The circle marks the
value under steady-state conditions.
Since we assumed a simplified model of lymphocyte toxicity under chemotherapy, we
can estimate the ratio of granulocytes and leukocytes under therapy, offering a possibility
to validate the model. Results of the CHOP-14 regimen with Filgrastim application at
day 4 to 13 are displayed in Figure 9. This ratio was estimated to be clearly not constant
varying between 68% and 98%.
Validation of the model
A few datasets were kept in reserve in order to validate our model. The phase 1 data of
Varki et al. [63] were not used for model fitting as well as the data of CHOP chemotherapy
under Pegfilgrastim treatment of George et al. [65]. Compared to the CHOP data used
for model fitting, the data of George et al. [65] comprise G-CSF serum levels as well. Both
scenarios fit well with our model prediction (see Figure 10). No additional parameter
fittings were performed to model these scenarios.
Discussion
In the present paper, we developed an ordinary differential equations model of human
granulopoiesis under chemotherapy and G-CSF support. The model was built on the
basis of a former model of granulopoiesis of our group which now has been improved
primarily by the incorporation of a detailed pharmacokinetic and -dynamic model of two
G-CSF derivatives (Filgrastim and Pegfilgrastim). At this, the pharmacokinetic model was
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Figure 6 (Effect of G-CSF delay): Effect of the delay parameter of G-CSF action on cell-counts of
specific cell compartments.
adopted from similar models developed for G-CSF applications in mice and rats devel-
oped by our group. Unknown model parameters were obtained by fitting the predictions
of the model to available datasets. The combined pharmacokinetic and -dynamic model
correctly predicts the time course of a variety of datasets comprising single or multiple
injections of G-CSF into healthy volunteers or patients under CHOP chemotherapy. We
were able to describe the differences between the G-CSF derivatives by a set of differ-
ent pharmacokinetic- and -dynamic parameters. The model was validated on the basis of
datasets not used for model fitting.
The presented model is by far not the first attempt to model granulopoiesis or
G-CSF applications. Published models comprise for example pure pharmacokinetic
models [25,46], pharmacokinetic and -dynamicmodels of G-CSF application on the cellu-
lar level [49], in healthy volunteers [50,51,70], for the treatment of cyclic neutropenia [71],
for high-dose chemotherapy with stem cell transplantation [72,73] or for conventional
chemotherapy patients [74,75]. We developed a model of human granulopoiesis under
chemotherapy in the past including a preliminary model of Filgrastim application [40].
To the best of our knowledge, there is so far no granulopoiesis model of humans under
conventional chemotherapy comprising a detailed pharmakokinetic- and dynamic model
of the two G-CSF derivatives Filgrastim and Pegfilgrastim. This combination allows us to
derive clinically meaningful applications of the model.
As mentioned, the presented model was based on a former model of our group. This
model was based on biologically plausible assumptions regarding the production of
mature granulocytes via a cascade of bonemarrow cell stages, the action of chemotherapy
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Figure 7 (Effect of chemotherapy delay): Effect of the delay parameter of the chemotherapy studied
for the CHOP regimen.
and the action of growth factor mediated feedback loops. Equations describe the fluxes
between cell compartments. G-CSF was modelled as the major regulatory element of
both, the transition time and the amplification within the compartments. Chemotherapy
was modelled by an instantaneous and transient cell loss of all bone marrow cell stages.
Since these basic model assumptions were intensively discussed in our former paper [40]
we will focus on our new model assumptions and parameters in the following.
The major improvement of our model is the incorporation of a detailed pharmacoki-
netic model of the two G-CSF derivatives Filgrastim and Pegfilgrastim. Both are widely
used in clinical practice in order to ameliorate leukopoenia during cancer chemotherapy.
The pharmacokinetic model was constructed in complete analogy to the pharmacokinetic
models which we developed for mice and rats recently [29,36]. That is, we made the same
physiological assumptions and used the same model equations but different parameters.
Furthermore, we used the same model equations for both drugs assuming that pharma-
cokinetic differences between the drugs can be traced back to different parameters rather
than different mechanisms of action.
The drugs were typically injected into the subcutaneous tissue resulting in a delayed
absorption by the circulating blood compartment probably via lymphatic absorption [45].
The delay was modelled by a set of concatenated first-order differential equations rather
than a fixed time delay. We showed in the past that this kind of modelling is equivalent to
a Gamma-distributed transition time, which is biologically plausible. At this, the variance
is determined by the number of subcompartments [40]. However, this variance appears
to be of lesser importance for the model behaviour. In analogy to [36], we observed that
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Figure 8 (Comparison of model and data for chemotherapy scenarios): Comparison of model and
data for the CHOP-21 regimen and time intensified CHOP-14 regimen supported by various
Filgrastim and Pegfilgrastim schedules. The solid line is the model prediction. Dots are patient medians at
corresponding time points and the grey lines mark the interquartile range of the data. All scenarios are based
on the same model parameters.
a number of subcompartments between two and ten would also work well. To reduce the
computational in the present model, we used the smaller number.
Data collected in mouse and rat experiments suggested that subcutaneously injected
G-CSF has a dose-dependent bioavailability [29,36]. Therefore, we introduced a loss
term into the equations of the subcutaneous compartment. Since there is some evidence
of reversible protein binding of G-CSF molecules, we modelled a first order transition
between the blood compartment and a peripheral compartment [46].
Our model assumptions regarding endogenous production of G-CSF are speculative.
We assumed that the production is regulated between a minimum and a maximum value
in dependence on bonemarrow cellularity [47]. In steady-state, the production is constant
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CHOP 14, elderly patients, Filgrastim day 4−13
Figure 9 (Ratio of granulocytes and leukocytes): Based onmodel simulations, the ratio of
granulocytes and leukocytes under CHOP-14 chemotherapy is predicted.
in order to sustain a fixed serum concentration determined by averaged data from the
literature.
Degradation of G-CSF was modelled by two independent processes, an unspecific
renal clearance modelled by a first order transition and a specific degradation via neu-
trophil elastase or G-CSF receptors. All three degradation mechanisms are biologically
well understood but their relative importance is unknown (see discussed literature in
section “Pharmacokinetic model assumptions”). The specific degradation was modelled
by a Michaelis-Menten kinetic which was assumed to be proportional to the number of
granulocytes. For the degradation mechanism due to neutrophil elastase, this assumption
seems to be appropriate [21]. On the other hand, since G-CSF receptors are also present
in bone marrow progenitors and precursors [42], it appears to be less appropriate for
the receptor-mediated clearance mechanism. Nevertheless, we assumed proportionality
as the most parsimonious model resulting in a good agreement of predictions and data.
The assumption also worked well for the pharmacokinetic modelling in mice [36] but
not for rats [29]. Moreover, we experimented with alternative model assumptions assum-
ing consumption of G-CSF by both, mature neutrophils and precursors which did not
significantly improve the quality of our model predictions.
Variable numbers of G-CSF receptors per cell were observed in dependence on the
G-CSF level [56]. Modelling this obervation would require additional assumptions and
parameters. We decided to skip this in the current version of the model in view of the
relatively good quality of model predictions in the clinical scenarios considered so far.
Scholz et al. Theoretical Biology andMedical Modelling 2012, 9:32 Page 22 of 28
http://www.tbiomed.com/content/9/1/32














































































































Figure 10 (Validation of model): Validation of the model on the basis of two datasets not used for
model fitting. Solid line is the model prediction. Dots and dotted lines are the data and the interpolated
data respectively.
The model equations worked well to explain the dynamics of G-CSF serum concen-
trations after single or multiple injections of Filgrastim or Pegfilgrastim in healthy or
diseased people. The same equations worked also well for a third G-CSF derivative,
namely Maxy-G34, which is a novel G-CSF derivative currently under development by
Maxygen Inc. However, due to a confidentiality agreement with Maxygen Inc., the results
are not shown in the present paper.
In order to make predictions regarding the response of granulopoiesis after the appli-
cation of G-CSF, it was necessary to attach a pharmacodynamic model of G-CSF appli-
cations. Since there is some evidence that the pegylations of the Pegfilgrastim molecule
interact with its binding affinity to the G-CSF receptor [26-29], we decided to assume
different regulation functions for Filgrastim and Pegfilgrastim. Hence, Z-functions of the
transition times and amplifications in CG, PGB and MGB are assumed to be different
for Filgrastim and Pegfilgrastim. On the other hand, we assumed the same Z-functions
for Filgrastim and endogenous G-CSF. Due to the fact that Filgrastim/endogenous G-CSF
and Pegfilgrastim were assumed to be different regarding Z-functions, it was necessary to
merge the superimposing effects of Pegfilgrastim and endogenous G-CSF or concurrent
Pegfilgrastim and Filgrastim applications as well. This was solved by a weighting factor
which is regulated between zero and one in dependence on the ratio of Pegfilgrastim
and Filgrastim or endogenous G-CSF in the system. If the Pegfilgrastim concentration
is high or low, then the system is mainly influenced by the Z-function of Pegfilgrastim
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or Filgrastim respectively. Although this assumption is plausible, the complete regula-
tion mechanism via the combined Z-functions must be considered as speculative, since
especially the shape of the regulation functions can hardly be observed or measured.
Another speculative mechanism introduced into our model update was the delayed
effect of G-CSF action. By model fitting, we estimated that the corresponding delay time
is about 6h which appears to be in the right order of magnitude compared to the dynamics
presented in [57]. However, the overall impact of the delay on model dynamics is limited.
At least for the scenarios considered in the present paper, it is not critical for the quality
of the agreement of model and data.
Furthermore, some adjustments were performed regarding chemotherapy modelling.
Instead of an instantaneous cytotoxic effect of chemotherapy assumed in our former
model version, we now assume a delayed effect to account for available data of the dynam-
ics of bone marrow cell stages after chemotherapy applications in mice [58]. The delay
parameter was assumed to be constant for all cell stages but specific for the applied drugs
or drug combinations and was modelled by a cascade of first order transitions. This mod-
elling is rather a phenomenological than a mechanistic approach since the delay is caused
by many factors such as toxification of the applied drugs at different time scales, transient
cell cycle arrests of cells and delayed apoptosis of cells due to irreversible damage [58].
Another improvement of our model is due to a semi-explicite modelling of lympho-
cyte toxicity. This was necessary in order to apply the model to a sufficiently large dataset
of time courses of both, granulocytes and leukocytes as well. In our former model, we
assumed proportionality of granulocytes and leukocytes during G-CSF application or
chemotherapy which is only roughly correct [38] and further unpublished data of our
chemotherapy studies). To avoid a complete cell kinetic model of lymphopoiesis requir-
ing a large set of new and unknownmodel parameters, lymphocyte counts were modelled
by a separate simple characteristic. We assumed no effect of G-CSF on lymphopoiesis
but a toxic effect of chemotherapy modelled by an exponential depletion of lymphocytes
according to a (delayed) chemotherapy toxicity function. This toxicity is again specific for
the drugs or drug combinations applied. The resulting model was able to explain the time
courses of leukocytes and granulocytes under G-CSF or chemotherapy adequately within
the framework of one model.
The model is based on a relatively large set of parameters. Due to missing bone mar-
row data during chemotherapy and growth factor application, only a limited knowledge
regarding the required cell-kinetic and toxicity parameters is available. Rough ranges for
transition times and amplification rates in steady-state or under stimulation by G-CSF
were obtained from the literature. But especially values under minimal stimulation, the
sensitivity parameters of the Z-functions and the toxicity parameters are not available
from literature data. Hence, many model parameters were determined indirectly by fit-
ting the predictions of the model to available datasets. For this purpose, we collected a set
of suitable data from the literature and clinical trials for which we have access to raw data.
Densely measured time courses of G-CSF serum levels after application in combination
with granulocyte or leukocyte counts after chemotherapy and different G-CSF schedules
are especially useful. Data of patients were pooled to construct a model that fits to the
median of patients. A unique parameter set was identified which is valid for all scenar-
ios considered. No adjustments were performed in order to fit single scenarios. Not all
datasets were used for model fitting enabling an opportunity for model validation.
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Despite of the utilization of several datasets comprising different G-CSF dosing and
timing schedules with and without chemotherapy, there remained a large uncertainty
regarding parameter estimates, and consequently, the current parameter settings must be
considered as preliminary. This is especially true for parameters with a low impact on our
fitness function in the scenarios considered as demonstrated by our sensitivity analysis.
Additionally, the toxicity parameters show some degree of dependence in the sense that
a higher toxicity at one cell stage can to some degree be compensated by a lower toxicity
at a subsequent cell stage and vice versa. Consequently, further datasets and validation
scenarios are required to improve the confidence regarding our parameter settings.
The estimates of our pharmacokinetic parameters resulted in a good fit of all
time series data of G-CSF serum concentration for both Filgrastim and Pegfilgras-
tim applications as well. The estimated values fit well to our biological under-
standing of the drugs. Due to the pegylation of the drug, it was expected that
the unspecific renal clearance is significantly reduced for Pegfilgrastim, which is in
agreement with our parameter estimates. We also estimated a reduced specific degra-
dation of Pegfilgrastim which could be explained by a reduced receptor binding
affinity or hydrophilic properties of pegylated molecules [26,27,76]. We also made
the same observation for our pharmacokinetic models constructed in mice and rats
[29,36]. Protein binding was estimated to be almost negligible for Filgrastim but impor-
tant for Pegfilgrastim in agreement with our observations in mice [36]. Finally, the esti-
mated distribution volumes are in rough agreement with findings of other authors [50,77].
The estimates of our cell-kinetic, pharmacodynamic and toxicity parameters also
resulted in a good fit of the time courses of granulocytes and leukocytes after application
of chemotherapy, G-CSF or combinations of it. Possible exceptions are cell counts mea-
sured shortly after the first application of Filgrastim, which seem to be underestimated in
some scenarios. We conclude that the model works well on a day-wise scale but might be
unable to explain short-term or transient effects of G-CSF applications e.g. on the scale
of hours. Modelling such short-term effects would require a better database, since almost
all available time courses of granulocytes and leukocytes were measured at most at a day-
wise scale. However, in order to make predictions regarding the efficiency of different
G-CSF schedules, we are also more interested in the long-term dynamics of granulocytes
and leukocytes in the course of the therapy rather than short-term effects after single
injections.
Estimates of the pharmacodynamic parameters of Filgrastim and Pegfilgrastim suggest
that Filgrastim has a higher potency to stimulate the bone marrow. This is in agreement
with our biological understanding that pegylation reduces the receptor binding affin-
ity. An analogous observation was made for Pegfilgrastim and the novel drug Maxy-G34
which has even more pegylation sites than Pegfilgrastim [29].
Although modelling of chemotherapy was not the primary goal of the present paper,
it was necessary to model at least a few conventional chemotherapy regimen to study
the pharmacokinetic properties of the G-CSF derivatives under granulopenic conditions.
Chemotherapy was modelled as a transient delayed toxic effect on all bone marrow cell
stages. Corresponding toxicity parameters are specific for the bone marrow cell stages
and the drugs and drug concentrations used. For the development of our model, we used
the data of the most simple chemotherapy regimen CHOP. With our toxicity parameter
estimates one obtains a good fit of all CHOP regimen with different G-CSF schedules.
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Other conventional chemotherapies were modelled by assuming different toxicity
parameters but the same cell kinetic model. Corresponding model simulations will be
demonstrated in a separate paper of our group comprising about 20 different chemother-
apy scenarios. Generally, the model can be applied to arbitrary conventional chemother-
apy regimens for which data of leukocyte or granulocyte time courses are available for
at least one G-CSF scheduling. Based on these data, sets of toxicity parameters of cor-
responding chemotherapies can be estimated. Using these parameters, it is possible to
make clinically relevant predictions regarding the time course of G-CSF serum concen-
trations, bone marrow cell stages and mature cell counts in circulation under different
G-CSF schedules, allowing to optimize G-CSF treatment. We will exploit the clinically
relevant applications of our model in the near future.
Conclusions
We established a human pharmacokinetic and -dynamic model of Filgrastim and Pegfil-
grastim applications under cytotoxic chemotherapy. The model is able to explain a large
number of clinical time series data of G-CSF serum concentrations, granulocytes and
leukocytes of patients treated with G-CSF and with or without chemotherapy. A unique
parameter set valid for all scenarios was established by fitting the predictions of the model
to clinical data. The model was validated on a set of scenarios not used for parameter fit-
ting. Differences between Filgrastim and Pegfilgrastim could be traced back to biologically
plausible differences in parameter estimates. Effects of chemotherapy can be quantified
by a set of toxicity parameters. Given these toxicity parameters, the model can be used
to simulate the dynamics of G-CSF, bone marrow cell stages and circulating granulocytes
or leukocytes of yet untested G-CSF schedules. The model is currently applied in the
planning phase of clinical trials in order to optimize G-CSF treatment.
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